QC
CATX icon

Quadrature Capital’s Perspective Therapeutics CATX Stock Holding History

Quadrature Capital’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$150K Buy
+44,075
New +$167K ﹤0.01% 1414
2025
Q4 		– Sell
-24,221
Closed -$83.7K – 1287
2025
Q3 		$83.7K Buy
+24,221
New +$88.3K ﹤0.01% 898
2025
Q2 		– Sell
-15,158
Closed -$32.4K – 1086
2025
Q1 		$32.4K Buy
+15,158
New +$45.5K ﹤0.01% 1009

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Quadrature Capital's CATX Position: Q2 2026 in Review

Quadrature Capital opened a new position in Perspective Therapeutics (CATX) in Q2 2026: 44,075 shares worth $150K. The stake represents ﹤0.01% of the portfolio and ranks #1414 among its holdings. This is a return to the name: Quadrature Capital previously reported a position in CATX as recently as Q3 2025.

Quadrature Capital first reported a position in CATX in Q1 2025 and has held it in 3 quarters since. 131 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • Quadrature Capital held 44,075 shares of Perspective Therapeutics worth $150K as of Q2 2026.
  • Perspective Therapeutics was a new Quadrature Capital position in Q2 2026.
  • Perspective Therapeutics made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #1414 holding.
  • Quadrature Capital first reported a position in Perspective Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • 131 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.